Cue Biopharma

Historical price data

Cue Biopharma is developing precision immunotherapies using its Immuno-STAT™ platform to selectively engage and modulate specific T cell populations, with an initial focus on autoimmune conditions and cancer. The company has established strategic collaborations with industry leaders like Boehringer Ingelheim and is advancing its lead asset, CUE-401, toward clinical development. Despite a challenging financial position with a low market valuation, its targeted approach represents a differentiated strategy in the competitive biologics landscape.

Proprietary Immuno-STAT™ platform engineers bifunctional biologics that use a pMHC complex for selective T cell receptor engagement and an integrated co-stimulatory/inhibitory domain to deliver a precise therapeutic signal.

Faces competition from companies developing antigen-specific tolerance therapies in autoimmunity and TCR-based/bispecific therapies in oncology. Differentiates via its off-the-shelf, pMHC-targeted biologics with integrated native signaling, but must prove clinical advantage against established and emerging modalities.